676results about "Disease diagnosis" patented technology

Methods and kits are provided for diagnosing of neuropsychiatric syndromes concurrent with SLE (NPSLE) and for determining whether an SLE subject is at risk of developing a neuropsychiatric disease.

Methods, kits, and systems for assessing the risk of a human subject for developing a cancer, including genetic risk assessment, clinical risk assessment, and combinations of both to improve risk analysis. Technologies utilize, among other things, analyzing a sample of DNA obtained or derived from a subject to detect the genotype for a plurality of test genomic loci.

The present invention relates to a method of a predicting clinical outcome for a subject diagnosed with epithelial cancer, such as oral squamous cell carcinoma, as well as to biomarkers for use in the method.

The present invention provides methods for the detection of aggressive prostate cancer, and methods for detecting aggressive prostate cancer based on comparisons to a mixed control population of subjects with non-aggressive prostate cancer or not having prostate cancer.

Use of N-oleoylethanolamide(OEA) or a microbiota OEA producer, such as Eubacterium rectale, in the preparation of medicament for the treatment of irritable bowel syndrome (IBS).

The present disclosure features anti-tumor necrosis factor receptor superfamily (TNFRSF), anti-tumor necrosis factor superfamily (TNFSF), anti-CD28, and anti-ICOS antibodies and antigen-binding fragments thereof having amino acid modifications at the Fc domain, and uses of these antibodies or antigen-binding fragments for modulating immune responses. The antibodies and antigen-binding fragments thereof can be used to treat various cancers, autoimmune disorders, neurological disorders, infectious diseases, inflammatory diseases, and transplant rejection.

A method for detecting an immune-mediated inflammatory disease characterized by an increase in expression of MMP12, in a subject, a diagnostic drug containing a substance that specifically interacts with MMP12, and a therapeutic agent containing an MMP12 inhibitory substance.

The present invention relates to a method for detecting immuno-checkpoint blockade (ICB)-induced hypophysitis or a risk thereof in a living organism, a test kit for carrying out the method and a method for treating and / or prophylaxis ICB-induced hypophysitis or a risk thereof in a living organism.

The present invention relates to methods for diagnosing stage B2 degenerative mitral valve disease (DMVD) in dogs, methods for determining the probability that a dog has stage B2 DMVD, methods for training models for predicting stage B2 DMVD in dogs, and related computer programs and systems.

The present invention provides a composition for diagnosing age-related macular degeneration (AMD) using proteomic analysis and biomarkers, a method for providing information for diagnosing AMD, and a method for screening substances for treating AMD, wherein the composition for diagnosing age-related macular degeneration (AMD), includes a preparation for measuring the mRNA or protein expression level of an age-related macular degeneration-related biomarker.

This disclosure provides a method of treating a neurodegenerative disease that includes administering to a subject in need thereof an effective amount of an agent that specifically reduces a level or activity of protein kinase A regulatory (PKA) subunit 1β (R1β).

The present invention belongs to the technical field of sensorineural hearing. Provided is the use of SPTBN1 as a target in the treatment of GJB2-related sensorineural hearing loss. The use comprises: the construction of a stably transfected cell line, wherein: HEK293T cells are cultured using a DMEM culture medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin in a humidified incubator at 37ºC with 95% air and 5% CO2, and when the cells reach 80%-90% confluence, cell passage is performed; IP-MS analysis, wherein: protein complexes are purified using Protein A / G immunoprecipitation magnetic beads, a portion of the extracted proteins is used as input, and then 2 μg of anti-Cx26 antibody is added to the remaining protein extract, same are gently pipetted and mixed, and incubated on a rotating shaker at 4℃ overnight; immunofluorescence observation of the co-localization of Cx26 and SPTBN1, wherein: a stably transfected cell line expressing WT-Cx26 and Mut-Cx26 is constructed; and co-immunoprecipitation (Co-IP) validation, wherein: a stably transfected cell line expressing WT-Cx26 is constructed. The present invention overcomes the limitations of therapeutic methods, such as the relatively low targeting specificity and short therapeutic time windows associated with full-length protein supplementation via gene therapy, thereby providing new insight into GJB2-related hearing loss, and a new target and a new treatment for same.

Provided are methods of treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), e.g., TMA after HSCT, in human patients having elevated levels of thrombomodulin (TM) and syndecan-1 (SYND1) compared to normal reference ranges of TM and SYND1, using an anti-C5 antibody and / or an anti-CFB antibody . Further provided are methods of treating a patient having HSCT-TMA comprising: (1) obtaining or having obtained a sample (e.g., blood or plasma sample) from the patient, (2) determining or having determined elevated TM and SYND1 levels in the sample compared to normal reference ranges of TM and SYNDI, respectively, and (3) administering to the patient an anti-C5 antibody or an anti-CFB antibody in an amount and with a frequency sufficient to treat HSCT-TMA after elevated TM and SYND1 levels have been determined. In one embodiment, the methods further comprise determining or having determined elevated Ba levels in the sample compared to a normal reference range for Ba. In another embodiment, the methods further comprise determining or having determined an elevated HSPG level in the sample compared to a normal reference range for HSPG. Further provided are methods of identifying a patient having HSCT-TMA that is suitable for treatment with an anti-C5 antibody or an anti-CFB antibody, as well as methods for monitoring responsiveness of a patient having HSCT-TMA to treatment with an anti-C5 antibody or an anti-CFB antibody.

The application belongs to the technical field of molecular biology, and particularly relates to metabolic markers for evaluating the prognosis of patients with hypertrophic cardiomyopathy and application thereof. The application determines that one or more of 3-hydroxyrilotene, asparagine-lysine, cyclohexylamine, arachidonic acid, aconitic acid, propionyl carnitine, ceramide, tryptophan, 3-hydroxysebacic acid, traumatic acid, phosphatidylcholine, alanine-proline, lysophosphatidylcholine, taurine and S-garlicin cysteine are related to the prognosis of hypertrophic cardiomyopathy, can evaluate the prognosis of patients with hypertrophic cardiomyopathy after undergoing muscle resection of interventricular septum, and shows accurate judgment on all-cause death or rehospitalization, cardiovascular events and postoperative new-onset arrhythmia. Finally, all the prognostic biomarkers are reproduced in an independent cohort, which is helpful for postoperative risk evaluation of patients with hypertrophic cardiomyopathy, has high specificity and high sensitivity.

A method for determining whether a subject is at risk for having a progressing or high-grade pre-invasive lesion, nodule or small mass, or having a solid malignant tumour is described the method comprising: (i) determining a ratio of activated and / or exhausted T cells:naive and / or resting T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence or absence of a panel of biomarkers comprising Ki67 and CD39, or (ii) determining a ratio of activated and / or exhausted T cells:T cells which are not activated and / or exhausted T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence or absence of a panel of biomarkers comprising Ki67 and CD39, (iii) determining a proportion of activated and / or exhausted T cells as a percentage of T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence of a panel of biomarkers comprising Ki67 and CD39, and / or (iv) determining a proportion of activated and / or exhausted T cells as a percentage of T cells in a sample of blood obtained from the subject, wherein the T cells are CD4 T cells, and wherein the determining comprises analysing T cells using cytometry to detect the presence of a panel of biomarkers comprising FoxP3.

Disclosed herein are methods and kits to assess an absorbed dose of ionizing radiation and / or the severity of tissue injury from radiation in a patient. Also disclosed are algorithms used to calculate an absorbed dose of radiation based on biomarker measurements of a plurality of biomarkers that are altered relative to a normal control in the event of radiation exposure.

The presently described and claimed technology relates immunoassay methods of assessing a subject's Alzheimer's Disease status and zygosity for the APOE ε4 allele.

Embodiments may provide capability to predict the 10-year risk of local recurrence of ductal carcinoma in situ (DCIS) conditions or other non-invasive carcinomas in situ. Embodiments may evaluate the severity and frequency of numerical and structural CA present within DCIS, and may assign a quantitative centrosomal amplification score (CAS) to each sample. For example, a method of determining the risk profile of a carcinoma in situ in a patient may comprise determining severity and frequency of numerical and structural centrosome amplification present within a sample of a carcinoma in situ from the patient and determining at least one centrosome amplification score (CAS) value for the sample based on the determined severity and frequency of numerical and structural centrosome amplification in the sample, wherein the determined at least one CAS value provides a measure of a level of a 10-year risk of local recurrence associated with the carcinoma in situ.

Described herein are methods and sensors for detecting a biomolecule analyte in a sample and uses related thereto. The sensor may utilise a substrate comprising a reference electrode, a counter electrode, and at least one working electrode; a sample activating composition in electrical contact with each of the electrodes and comprising a reducing agent and a complexing agent; and an electrical signal detector.

The present invention relates to agents for measuring the expression of proteins or genes encoding the proteins that are exclusively or specifically expressed in circulating tumor cells, or methods for preventing or treating cancer metastasis by controlling the expression of the proteins or the genes. The present invention provides a method for detecting cancer or cancer metastasis by identifying proteins or genes encoding proteins that are exclusively or specifically expressed in circulating tumor cells, and measuring their expression, and ultimately, may be effectively used for efficient prevention or treatment of cancer metastasis by inhibiting their expression.

The present invention relates to an antibody specifically binding to a tryptophanyl-tRNA synthetase (WRS) protein and, more specifically, to: an antibody, or a fragment of the antibody, specifically binding to a polypeptide of an amino acid sequence represented by SEQ ID NO: 2 in a WRS protein; a polynucleotide encoding the antibody and a vector comprising same; a cell transformed using same; and a use thereof.

The present invention relates to the field of oncology. In particular, the present invention relates to biomarkers for colorectal cancer and their use for diagnosing or staging colorectal cancer. The biomarkers of the present invention allow for the sensitive and accurate diagnosis of colorectal cancer and the differentiation between non-metastatic and metastatic colorectal cancer.

The present invention relates to compositions comprising photoreceptor precursor cells (PRPs), as well as methods of generating the composition of PRPs and methods of using the composition of PRPs for regenerative cell therapy.

This document provides methods and materials involved in assessing mammals with acute decompensated heart failure (ADHF), as well as methods and materials involved in assessing outcomes. For example, methods and materials for using the level of plasma CNP and the level of urinary CNP to determine whether or not a mammal is developing or likely to develop more severe ADHF, as well as methods and materials for using the level of plasma CNP and the level of urinary CNP to identify patients having an increased likelihood of experiencing a poor outcome are provided.

The application belongs to the technical field of biology and particularly relates to application of phosphatidylglycerol. The phosphatidylglycerol PG (20:4_22:6) is used as a biomarker, and through analysis on metabolites of follicular fluid, the application realizes diagnosis of decreased ovarian reserve (DOR) with high sensitivity, high specificity and high accuracy.

An isolated antigen binding protein, which includes at least one CDR of a heavy chain variable region and at least one CDR of a light chain variable region and a method to encode an isolated nucleic acid molecule. A vector with the nucleic acid molecule. A cell with the nucleic acid molecule. A pharmaceutical composition with the isolated antigen binding protein. A method for preventing, alleviating or treating a C5-related disease or disorder. A method for detecting C5 in a sample.